A Phase-IV Study Comparing Standard Release Tacrolimus (Prograf) vs Prolonged-Release Tacrolimus (Advagraf) Monotherapy as Maintenance Immunosuppression After Induction With Alemtuzumab in Kidney Transplantation.

Trial Profile

A Phase-IV Study Comparing Standard Release Tacrolimus (Prograf) vs Prolonged-Release Tacrolimus (Advagraf) Monotherapy as Maintenance Immunosuppression After Induction With Alemtuzumab in Kidney Transplantation.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Tacrolimus (Primary) ; Alemtuzumab
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Acronyms TAESR
  • Most Recent Events

    • 19 May 2013 One-year results presented at the American Transplant Congress - 13th Joint Congress of the American Society of Transplant Surgeons and the American Society of Transplantation.
    • 10 Aug 2012 Status changed from recruiting to active, no longer recruiting.
    • 27 Jun 2011 Planned end date changed from 1 Dec 2010 to 1 Mar 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top